<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An attempt has been made to investigate drug elimination in patients with <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="31225">Antipyrine</z:chebi> was chosen as a model drug </plain></SENT>
<SENT sid="2" pm="."><plain>The patients were divided into three groups depending upon clinical, biochemical, radiologic and histologic findings; (1) mild (Idiopathic <z:hpo ids='HP_0001409'>portal hypertension</z:hpo>, extrahepatic <z:e sem="disease" ids="C0265029" disease_type="Disease or Syndrome" abbrv="">portal vein obstruction</z:e> and <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e>); (2) moderate (<z:hpo ids='HP_0002639'>Budd-Chiari syndrome</z:hpo> and amoebic <z:hpo ids='HP_0100523'>liver abscess</z:hpo>); (3) severe (<z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0012115'>hepatitis</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> active <z:hpo ids='HP_0012115'>hepatitis</z:hpo> and <z:hpo ids='HP_0001394'>cirrhosis</z:hpo>) </plain></SENT>
<SENT sid="3" pm="."><plain>A prolongation in <z:chebi fb="0" ids="31225">antipyrine</z:chebi> half-life (t1/2) was observed in 108 patients with <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e> (24.59 +/- 1.72 h) as compared to 12 controls (11.63 +/- 0.86 h) </plain></SENT>
<SENT sid="4" pm="."><plain>Similarly, metabolic clearance rate was decreased in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disorders</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Among liver function tests, <z:chebi fb="0" ids="31225">antipyrine</z:chebi> t1/2 showed a significant correlation with serum albumin and prothrombin time index </plain></SENT>
<SENT sid="6" pm="."><plain>After <z:chebi fb="0" ids="8069">phenobarbitone</z:chebi> administration, <z:chebi fb="0" ids="31225">antipyrine</z:chebi> clearance studied in 37 patients showed a significant decrease in t1/2 and an increase in MCR </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="31225">Antipyrine</z:chebi> t1/2 in 26 patients after recovery was comparable to those of controls </plain></SENT>
</text></document>